X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2260) 2260
Publication (287) 287
Book Chapter (36) 36
Book Review (26) 26
Magazine Article (4) 4
Book / eBook (2) 2
Dissertation (2) 2
Conference Proceeding (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1759) 1759
index medicus (1278) 1278
cholangiocarcinoma (1256) 1256
male (895) 895
oncology (880) 880
female (793) 793
cancer (771) 771
cholangiocarcinoma - drug therapy (752) 752
middle aged (689) 689
aged (621) 621
bile duct neoplasms - drug therapy (602) 602
cholangiocarcinoma - pathology (579) 579
chemotherapy (542) 542
bile duct neoplasms - pathology (478) 478
animals (448) 448
adult (436) 436
cell line, tumor (419) 419
intrahepatic cholangiocarcinoma (395) 395
gastroenterology & hepatology (369) 369
treatment outcome (363) 363
apoptosis (335) 335
tumors (326) 326
gemcitabine (321) 321
bile ducts, intrahepatic (313) 313
prognosis (301) 301
surgery (300) 300
deoxycytidine - analogs & derivatives (293) 293
expression (272) 272
antineoplastic combined chemotherapy protocols - therapeutic use (257) 257
cholangiocarcinoma - metabolism (257) 257
carcinoma (253) 253
aged, 80 and over (252) 252
survival (251) 251
metastasis (244) 244
mice (240) 240
liver (238) 238
bile ducts, intrahepatic - pathology (232) 232
hepatocellular-carcinoma (229) 229
research (229) 229
medical prognosis (222) 222
cholangiocarcinoma - genetics (221) 221
health aspects (212) 212
bile duct neoplasms - metabolism (210) 210
liver cancer (207) 207
cancer therapies (206) 206
apoptosis - drug effects (204) 204
biliary tract neoplasms - drug therapy (198) 198
proteins (195) 195
cell proliferation - drug effects (189) 189
cholangiocarcinoma - surgery (186) 186
cisplatin (179) 179
antineoplastic agents - therapeutic use (178) 178
analysis (174) 174
deoxycytidine - administration & dosage (167) 167
bile duct neoplasms - surgery (166) 166
gene expression (164) 164
cholangiocarcinoma - mortality (163) 163
retrospective studies (162) 162
bile duct neoplasms - genetics (160) 160
patients (159) 159
kinases (158) 158
bile duct neoplasms - mortality (157) 157
pharmacology & pharmacy (155) 155
antineoplastic agents - pharmacology (154) 154
hilar cholangiocarcinoma (154) 154
care and treatment (153) 153
neoplasm staging (152) 152
studies (152) 152
therapy (152) 152
hepatocellular carcinoma (150) 150
liver neoplasms - drug therapy (148) 148
biliary tract cancer (147) 147
liver neoplasms - pathology (141) 141
medicine (140) 140
survival rate (138) 138
medicine & public health (137) 137
cholangiocarcinoma - therapy (136) 136
survival analysis (136) 136
article (135) 135
mice, nude (135) 135
biliary-tract cancer (130) 130
research article (128) 128
risk factors (128) 128
mutation (126) 126
cell growth (125) 125
diagnosis (125) 125
cell proliferation (124) 124
disease-free survival (124) 124
phase-ii (124) 124
growth (122) 122
signal transduction (122) 122
immunohistochemistry (120) 120
cell cycle (119) 119
combined modality therapy (119) 119
bile duct neoplasms - therapy (118) 118
cholangiocarcinoma - diagnosis (116) 116
phase-ii trial (115) 115
xenograft model antitumor assays (112) 112
gallbladder carcinoma (109) 109
cell biology (105) 105
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2189) 2189
Japanese (57) 57
German (21) 21
French (9) 9
Korean (7) 7
Spanish (7) 7
Danish (3) 3
Russian (3) 3
Chinese (2) 2
Czech (1) 1
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Medicine, ISSN 1078-8956, 2017, Volume 23, Issue 12, pp. 1424 - 1435
Human liver cancer research currently lacks in vitro models that can faithfully recapitulate the pathophysiology of the original tumor. We recently described a... 
MEDICINE, RESEARCH & EXPERIMENTAL | CHOLANGIOCARCINOMA | STEM-CELLS | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE | ESTABLISHMENT | GENOME | CELL BIOLOGY | HEPATOCELLULAR-CARCINOMA | IN-VITRO EXPANSION | ADULT LIVER | EXPRESSION | INACTIVATING MUTATIONS | Cell Proliferation | Primary Cell Culture - methods | Humans | Gene Expression Regulation, Neoplastic | Transcriptome | Male | Antineoplastic Agents - therapeutic use | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - isolation & purification | Carcinoma, Hepatocellular - genetics | Liver Neoplasms - pathology | Bile Duct Neoplasms - genetics | Tumor Cells, Cultured | Bile Duct Neoplasms - drug therapy | Precision Medicine | Drug Screening Assays, Antitumor - methods | Organoids - pathology | Liver Neoplasms - genetics | Liver Neoplasms - drug therapy | Mice, SCID | Xenograft Model Antitumor Assays | Cholangiocarcinoma - pathology | Animals | Cholangiocarcinoma - drug therapy | Carcinoma, Hepatocellular - pathology | Cholangiocarcinoma - genetics | Mice, Inbred NOD | Mice | Bile Duct Neoplasms - pathology | Cell culture | Liver cancer | Development and progression | Usage | Models | Research | Propagation | Liver | Hepatocellular carcinoma | Tissues | Drug screening | Metastases | Utilities | Biomedical materials | Organoids | Xenografts | Bioindicators | Cholangiocarcinoma | Extracellular signal-regulated kinase | Cultures | Pharmacology | Gene expression | Chemical compounds | Screening | Hepatocytes | Biomarkers | In vivo methods and tests | Tumors | Cancer
Journal Article
Voprosy Onkologii, ISSN 0507-3758, 2018, Volume 64, Issue 2, pp. 171 - 174
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 726 - 736
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 08/2015, Volume 33, Issue 24, pp. 2617 - 2622
Journal Article
Biomedical Microdevices, ISSN 1387-2176, 3/2018, Volume 20, Issue 1, pp. 1 - 8
This study aimed to investigate the drug delivery efficacy and bio-effectiveness of a novel photodynamic therapy (PDT)-matrix drug delivery system for... 
Biomedical Engineering | Engineering | Photodynamic therapy (PDT) | Engineering Fluid Dynamics | Biological and Medical Physics, Biophysics | Stent | Nanotechnology | Cholangiocarcinoma | DIAGNOSIS | MANAGEMENT | HILAR CHOLANGIOCARCINOMA | ENDOSCOPIC PALLIATION | DRAINAGE | UNRESECTABLE CHOLANGIOCARCINOMA | ENGINEERING, BIOMEDICAL | NANOSCIENCE & NANOTECHNOLOGY | CANCER | GEMCITABINE | Drug-Eluting Stents | Dihematoporphyrin Ether - administration & dosage | Drug Delivery Systems - instrumentation | Reactive Oxygen Species - metabolism | Bile Duct Neoplasms - metabolism | Dihematoporphyrin Ether - pharmacokinetics | Apoptosis - drug effects | Photochemotherapy - methods | Humans | Antineoplastic Agents - administration & dosage | Cholangiocarcinoma - metabolism | Methacrylates - chemistry | Polymethacrylic Acids - chemistry | Cholangiocarcinoma - pathology | Cholangiocarcinoma - drug therapy | Photochemotherapy - instrumentation | Cell Line, Tumor | Drug Liberation | Antineoplastic Agents - pharmacokinetics | Bile Duct Neoplasms - pathology | Drug Delivery Systems - methods | Polyvinyls - chemistry | Bile Duct Neoplasms - drug therapy | Drugs | Medical colleges | Ethylene glycol | Drug delivery systems | Benzoyl peroxide | Photochemotherapy | Vinyl acetate | Stent (Surgery) | Cancer | Vehicles | Medical imaging equipment | Surgical implants | Membranes | Ethylene | Stenosis | Polyvinylpyrrolidone | Drug delivery | Peroxide | Implants | Diffusion | Stents | Polyurethane resins | Photodynamic therapy | Diffusion layers | Polyhydroxyethyl methacrylate | Polyurethane | Acetic acid | Viability | Species diffusion | Apoptosis
Journal Article
PLoS One, ISSN 1932-6203, 2010, Volume 5, Issue 5, p. e10630
Background: Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. The high risk of recurrence following surgical resection provides the rationale for... 
SURVIVAL | CELLS | DUCTAL ADENOCARCINOMA | MULTIDISCIPLINARY SCIENCES | HUMAN CHOLANGIOCARCINOMA | TUMOR-SUPPRESSOR GENE | PROGNOSTIC MARKERS | ACTIVATED AKT | EXPRESSION | GEMCITABINE | ENDOTHELIAL GROWTH-FACTOR | Multivariate Analysis | Recurrence | Oligonucleotide Array Sequence Analysis | Humans | Middle Aged | Male | MicroRNAs - metabolism | Carcinoma, Pancreatic Ductal - surgery | Carcinoma, Pancreatic Ductal - genetics | Pancreatic Neoplasms - drug therapy | Biomarkers, Tumor - metabolism | Female | Chemotherapy, Adjuvant | Gene Expression Regulation, Neoplastic - drug effects | Korea | Reproducibility of Results | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - surgery | Proportional Hazards Models | Pancreatic Neoplasms - genetics | Treatment Outcome | Carcinoma, Pancreatic Ductal - pathology | Carcinoma, Pancreatic Ductal - drug therapy | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | Italy | Aged | Biomarkers, Tumor - genetics | Cell Proliferation - drug effects | Fluorouracil - pharmacology | MicroRNAs - genetics | Cohort Studies | Drug Resistance, Neoplasm - drug effects | Immunohistochemistry | Medical research | Care and treatment | Prognosis | MicroRNA | Pancreatic cancer | Patient outcomes | Adjuvant treatment | Medicine, Experimental | Cancer | Adenocarcinoma | Therapy | Medical services | Chemoresistance | Cytotoxicity | Oncology | Paraffin | Tissues | Cancer therapies | Anticancer properties | Proteins | Transfection | Surgery | Bioindicators | Vascular endothelial growth factor | Cell survival | Internal medicine | Mortality | MiRNA | Hazards | Gene expression | Ribonucleic acid--RNA | Patients | Medicine | Pathology | Chemotherapy | Hospitals | Statistical models | MicroRNAs | Medical prognosis | Stem cells | Biomarkers | Mutation | Chemokines | Apoptosis | Tumors | RNA | Ribonucleic acid
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 819 - 828
Summary Background Gemcitabine plus a platinum-based agent (eg, cisplatin or oxaliplatin) is the standard of care for advanced biliary cancers. We investigated... 
Hematology, Oncology and Palliative Medicine | GROWTH-FACTOR RECEPTOR | MULTICENTER | CISPLATIN | ONCOLOGY | COLORECTAL-CANCER | CLINICAL-TRIALS | GALLBLADDER | COMBINATION | TUMORS | CHEMOTHERAPY | GALL-BLADDER CANCER | ras Proteins - genetics | Peripheral Nervous System Diseases - chemically induced | Proto-Oncogene Proteins p21(ras) | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Alanine Transaminase - blood | Organoplatinum Compounds - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Oxaliplatin | Common Bile Duct Neoplasms - drug therapy | Adult | Bile Ducts, Intrahepatic | Female | Bile Duct Neoplasms - genetics | Cetuximab | Neutropenia - chemically induced | Common Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Carcinoma - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Deoxycytidine - administration & dosage | Gallbladder Neoplasms - genetics | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Gallbladder Neoplasms - drug therapy | Aspartate Aminotransferases - blood | Cholangiocarcinoma - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Cholangiocarcinoma - genetics | Carcinoma - genetics | Aged | Mutation | Deoxycytidine - analogs & derivatives | Chemotherapy | Product development | Gemcitabine | Comparative analysis | Cancer
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2016, Volume 68, pp. 1 - 10
Abstract Purpose We performed a multi-centre phase I study to assess the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the orally available small... 
Hematology, Oncology and Palliative Medicine | Pharmacodynamics | MEK inhibitor | Phase I | Optimal biological dose | Pharmacokinetics | BRAF-MUTATED MELANOMA | MULTICENTER | SELUMETINIB PLUS DOCETAXEL | SAFETY | TRAMETINIB | CELL LUNG-CANCER | TRIAL | DOSE-ESCALATION | ONCOLOGY | DOUBLE-BLIND | AZD6244 ARRY-142886 | Lung Neoplasms - drug therapy | Pancreatic Neoplasms - metabolism | Nausea - chemically induced | Allosteric Regulation | Humans | Lung Neoplasms - metabolism | Middle Aged | Male | Fatigue - chemically induced | Ribosomal Protein S6 Kinases, 70-kDa - drug effects | Protein Kinase Inhibitors - adverse effects | Colorectal Neoplasms - drug therapy | Chromatography, Liquid | Proto-Oncogene Proteins c-akt - metabolism | MAP Kinase Kinase 1 - antagonists & inhibitors | Bile Duct Neoplasms - metabolism | Ribosomal Protein S6 Kinases, 70-kDa - metabolism | Administration, Oral | Carcinoma, Non-Small-Cell Lung - metabolism | Neoplasms - drug therapy | Maximum Tolerated Dose | Mesothelioma - metabolism | Mitogen-Activated Protein Kinase 3 - metabolism | Anorexia - chemically induced | Glycogen Synthase Kinase 3 beta - drug effects | Mitogen-Activated Protein Kinase 1 - metabolism | Neoplasms - metabolism | Phosphoproteins - drug effects | Mitogen-Activated Protein Kinase 1 - drug effects | Cholangiocarcinoma - metabolism | Chromatography, High Pressure Liquid | Diarrhea - chemically induced | Mitogen-Activated Protein Kinase 3 - drug effects | Pancreatic Neoplasms - drug therapy | Tandem Mass Spectrometry | Uterine Cervical Neoplasms - metabolism | Esophageal Neoplasms - metabolism | Adult | Female | Colorectal Neoplasms - metabolism | Bile Duct Neoplasms - drug therapy | Drug Eruptions - etiology | Abdominal Pain - chemically induced | Uterine Cervical Neoplasms - drug therapy | Glycogen Synthase Kinase 3 beta - metabolism | Mesothelioma - drug therapy | Cholangiocarcinoma - drug therapy | MAP Kinase Kinase 2 - antagonists & inhibitors | Protein Kinase Inhibitors - therapeutic use | Aged | Protein Kinase Inhibitors - pharmacology | Carcinoma, Non-Small-Cell Lung - drug therapy | Esophageal Neoplasms - drug therapy | Proto-Oncogene Proteins c-akt - drug effects | Care and treatment | Protein kinases | Mitogens | Cells | Tumors
Journal Article
PLoS Genetics, ISSN 1553-7390, 02/2014, Volume 10, Issue 2, p. e1004135
Author Summary Cholangiocarcinoma is a cancer that affects the bile ducts. Unfortunately, many patients diagnosed with cholangiocarcinoma have disease that... 
C-VIRUS-INFECTION | GROWTH-FACTOR RECEPTOR | BILIARY-TRACT CANCER | K-RAS MUTATIONS | RISK-FACTORS | GENETICS & HEREDITY | TUMOR-SUPPRESSOR GENE | HEPATITIS-C | PRIMARY SCLEROSING CHOLANGITIS | FLUKE-ASSOCIATED CHOLANGIOCARCINOMA | NEGATIVE BREAST-CANCER | Erlotinib Hydrochloride | Receptor, Epidermal Growth Factor - genetics | Prognosis | Receptor, Fibroblast Growth Factor, Type 2 - metabolism | Humans | Transcriptome | Imidazoles - administration & dosage | Molecular Targeted Therapy | Receptor, Epidermal Growth Factor - metabolism | Pyridazines - administration & dosage | Quinazolines - administration & dosage | Receptor, Fibroblast Growth Factor, Type 2 - antagonists & inhibitors | Bile Duct Neoplasms - genetics | Bile Duct Neoplasms - drug therapy | Bile Ducts, Intrahepatic - pathology | Pyrimidines - administration & dosage | Signal Transduction - genetics | Cholangiocarcinoma - pathology | Protein Kinase Inhibitors | Cholangiocarcinoma - drug therapy | Cell Line, Tumor | Cholangiocarcinoma - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Bile Duct Neoplasms - pathology | Mutation | Genome, Human | Receptor, Fibroblast Growth Factor, Type 2 - genetics | Sulfonamides - administration & dosage | Antimitotic agents | Analysis | Genomics | Research | Antineoplastic agents | Health aspects | Tumors | Studies | Hepatitis | Substance abuse treatment | Genetic engineering | Genomes | Kinases | Gene expression | Patients | Cancer
Journal Article